GSK Files For Additional Indication Of Glavamox Dry Syrup For Sinusitis In Japan
This article was originally published in PharmAsia News
GlaxoSmithKline has filed for the additional indication of the β-lactamase inhibitor combination Glavamox (amoxicillin trihydrate/clavulanate potassium) dry syrup for sinusitis in Japan, the company announced on May 30.
You may also be interested in...
Experts from the University of Chicago are advocating for helmet ventilation for COVID-19 patients. Medtech Insight spoke to acute nurse practitioner Aurika Savickaite who is helping lead an initiative to educate and raise awareness of the technology.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Sixty-nine guidance documents have been posted on the tracker since its last update.
The US company is bringing extra supplies of lopinavir/ritonavir into France but stresses that the combination treatment is not authorized for treating patients with the coronavirus.